A regulatory filing shows Johnson & Johnson can choose to terminate its partnership with Schering-Plough over anti-inflammatory drugs Remicade and golimumab in light of Schering-Plough's merger with Merck & Co. Ending the agreement would drag down annual sales of Remicade and projected revenue from golimumab, according to this article.

Related Summaries